Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab

Authors

  • Robert Königsberg Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna) – LB Cluster Translational Oncology, 3rd Medical Department – Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria

Abstract

IntroductionThe attempt to act on several signalling pathwaysinvolved in tumour development simultaneously appears to be more attractivethan attacking a single target structure alone. VEGF overexpression isfrequently observed in Her2/neu positive patients with breast cancer andover-expression of the proto-oncogene Her2/neu is associated with anup-regulation of VEGF. MethodsHere we present the case of a Her2/neu positivepatient with breast cancer who refused cytotoxic chemotherapy with itspotential side effects as well as mastectomy. Results andDiscussionThis patient received the combined doubleadministration of bevacizumab and trastuzumab for more than 4 years. This case report shows that (a) the combined double administration of bevacizumab andtrastuzumab is clinically highly effective. (b) The combinationof bevacizumab and trastuzumab is safe and non-toxic. (c) Bevacizumab andtrastuzumab can be used as long-term application.

Author Biography

Robert Königsberg, Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna) – LB Cluster Translational Oncology, 3rd Medical Department – Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria

Downloads

Published

2014-05-09

How to Cite

Königsberg, R. (2014). Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab. Radiology and Oncology, 48(2). Retrieved from https://www.radioloncol.com/index.php/ro/article/view/1999

Issue

Section

Clinical oncology